Friday, 15 January 2016

Big changes at the Moffat Partnership, the parent company of BritainsDNA and ScotlandsDNA

There seems to have been a big shake up at the Moffat Partnership, the parent company of BritainsDNA, ScotlandsDNA, CymruDNAWales, IrelandsDNA and YorkshiresDNA. According to reports filed yesterday at Companies House Alistair Moffat, Lindsay Moffat, Jim Wilson, Angelika Kritz-Wilson and Francis Rowan Oldfield De Courcy Hamilton stood down as directors on 9th December last year. Three new directors were appointed on 9th December: Timothy Charles Metcalfe, Dr. Nicholas Watson Ash and Dr. Nicholas Ivor Leaves. The three new directors all work for Source Bioscience, the company who process the Chromo2 DNA tests for the Moffat Partnership companies. Nick Ash is the CEO of Source Bioscience. Dr Nick Leaves is the company's Chief Operating Officer and Timothy Metcalfe is the Group Finance Director. It therefore looks very much as though the Moffat Partnership has been acquired by Source BioScience though I can find no official announcement. The various Moffat Partnership websites seem to be trading as normal.

Here is a description of Source BioScience from the company website:
With over 15 years of Sanger sequencing experience, the service operates from state of the art facilities in Nottingham, Cambridge, Oxford, Rochdale and BioCity Scotland, with European facilities in Ireland and Germany. The sequencing service provides unique benefits for the customer including an Overnight service, easy online ordering and SpeedREAD automated data delivery. 
Complimenting this, the next generation sequencing service for life science research, molecular pathology and clinical diagnostics utilises the Illumina MiSeq™ and HiSeq™ platforms to provide the most comprehensive and advanced service from GLP/GCP accredited laboratories. 
Contract research services feature a broad range of microarray, genotyping and gene expression applications on Affymetrix, Agilent, and Fluidigm platforms.
An extensive product portfolio includes over 20 million clones and over 200,000 antibodies, plus a wide range of research reagents for use in applications such as cell culture, immunology, nucleic acid analysis and cloning, gene expression and regulation. 
Source BioScience can offer researchers in academia and in the pharmaceutical industry the highest quality resources and innovative technology with maximum flexibility and cost effectiveness.
No doubt further announcements will be forthcoming in due course. It will be interesting to see what the company's plans are for the various Moffat Partnership websites.

©2016 Debbie Kennett

No comments: